Synthesis of paclitaxel (docetaxel) / 2-deacetoxytaxinine J dimers

Tetrahedron

Volumn 55, Issue 21, 1999, Pages 6567-6576

  Appendino, Giovanni ^a   Belloro, Emanuela ^a   Jakupovic, Sven ^a   Danieli, Bruno ^b   Jakupovic, Jasmin ^c   Bombardelli, Ezio ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b Dipartimento di Chimica Organica e Industriale   (Italy)

^c TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^d INDENA S P A   (Italy)

Author keywords

Antitumour compounds; Dimers; Taxoids

Indexed keywords

10 DEACETYLBACCATIN; 2' DEACETOXYAUSTROSPICATINE; DIMER; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE; TAXOID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG SENSITIVITY; DRUG SYNTHESIS; PLANT; PRIORITY JOURNAL;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033591156     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00290-2     Document Type: Article

References (41)

1. Part XXXIII in the Series "The Chemistry and Occurrence of Taxane Derivatives". Part XXXII: Barboni, L.; Lambertucci, C.; Ballini, R.; Appendino, G.; Bombardelli, E. Tetrahedron Lett. 1998, 39, 7177-7180.
2. Ford, J.M.; Hait, W.N. Pharmacol. Rev, 1990, 42, 155-192
3. Endicott, J.A.; Ling, V. Annu. Rev. Biochem. 1989, 58, 137-171.
4. Lautier, D.; Canitrot, Y.; Deeley, R.G.; Cole, S.P.C. Biochem. Pharmacol. 1996, 52, 967-977.
5. a) Reddy, D.S. Drugs Fut. 1997, 22, 653-660.
6. b) Robert, J. Drugs Fut. 1997, 22, 149-158.
7. Spencer, C.M.; Faulds, D. Drugs 1994, 48, 794-847.
8. Fulton, B.; Spencer, C.M. Drugs 1996, 57, 1075-1092.
9. Wills, P.; Phung-Ba, V.; Warnery, A.; Lechardeur, D.; Raissi, S.; Hidalgo, I.J.; Schermann, D. Biochem. Pharm. 1994, 48, 1528-1530. Non-P-gl-mediated mechanisms of resistance to paclitaxel are also known: Parekc, H.; Wiesen K.; Simpkins, H. Biochem. Pharmacol. 1997, 53, 461-470.
10. Wills, P.; Phung-Ba, V.; Warnery, A.; Lechardeur, D.; Raissi, S.; Hidalgo, I.J.; Schermann, D. Biochem.pharm. 1994, 48, 1528-1530. Non-P-gl-mediated mechanisms of resistance to paclitaxel are also known: Parekc, H.; Wiesen K.; Simpkins, H. Biochem. Pharmacol. 1997, 53, 461-470.
11. a) Kobayashi, J.; Hosoyama, H.; Wang, X.-X.; Shigemori, H.; Koiso, Y.; Iwasaki, S.; Sasaki, T.; Naito, M.; Tsuro, T. Bioorg. Med Chem. Lett. 1997, 7, 393.
12. b) Ojima, I.; Bounaud, P.-Y.; Takeuchi, C.; Pera, P.; Bernacki, R.J. Bioorg. Med. Chem. Lett. 1998, 8, 189-194.
13. Liang, J.-Y.; Min, Z.-D-; Niwa, M.Acta Chim. Sin. 1988, 46, 1053-1055.
14. Alloatti, G.; Penna, C.; Levi, R.C.; Gallo, M.P.; Appendino, G.; Fenoglio, I. Life Sci. 1996, 58, 845-852.
15. Bourgignon, J.-J. In The Practice of Medicinal Chemistry, Wermuth, G.G., Ed.; Academic Press, 1996, 261-293.
16. For reviews, see: (a) Chen, S.-H.; Farina, V. In The Chemistry and Pharmacology of Taxol® and Related Compounds; Farina, V., Ed.; Eisevier, 1995, pp.165-253.
17. (b) Georg, G.I.; Boge, T.C.; Cheruvallath, Z.S.; Clowers, J.S.; Harriman, G.C.B.; Hepperle, M.; Park, H. in Taxol: Science and Applications; Sufrhess, M., Ed.; CRC, Boca Raton, 1995, pp. 317-375.
18. Ojima, I.; Slater, J.C.; Michaud, E.; Kuduk, S.D.; Bounaoud, P.-Y.; Vrignaud, P.; Bissery, M.C.; Veith, J.M.; Pera, P.; Bernacki, R.J. J. Med. Chem. 1996, 39, 3889-3896.
19. a) Isolation of 4 from the European yew: Denis, J.-N.; Greene, A.E.; Guénard, D.; Guéritte-Voegelein, F.; Mangatal, L.; Potier, P. J. Am. Chem. Soc. 1988, 110, 5917-5919.
20. b) Isolation of 5 from T. x media Rehd.: Fenoglio, I.; Nano, G.M.; Vander Velde, D.O.; Appendino, G. Tetrahedron Lett. 1996, 37, 3203-3206.
21. Paclitaxel itself could not be directly employed for the synthesis of 3a, since its 2'-protected- and 2',7-diprotected (TES, Cbz) derivatives could not be selectively deacetylated at C-10.
22. The diol 9c was unreactive toward succinic anhydride. No reaction took also place when 7,10-diTES-10-deacetylbaccatin III was treated with this reagent.
23. Marder-Karsenti, R.; Dubois, J.; Bricard, L.; Guénard, D.; Guéritte-Voegelein, F. J. Org. Chem. 1997, 62, 6631-6637.
24. a) Wiegerinck, P.H.G.; Fluks, L.; Hammink, J.B.; Mulders, S.J.E.; de Groot, F.M.H.; van Rozendaal, H.L.M.; Scheeren, H.W. J. Org. Chem. 1996, 61, 7092-7100.
25. b) Poujol, H.; Mourabit, A.A.; Ahond, A.; Poupat, C.; Potier, P. Tetrahedron 1997, 53, 12575-1294.
26. 15a but can be efficiently carried out in DMF with only 1.1 equivalents of TES-C1 and imidazole.
27. Guéritte-Voegelein, F.; Sénilh, V.; David, B.; Guénard, D.; Potier, P. Tetrahedron 1986, 42, 4451-4460.
28. Stoemer, D.; Caron, S.; Heathcock, C.H. J. Org. Chem. 1996, 61, 9115-9125.
29. a) ZiChen, S.-H.; Huang, S.; Wei, J.; Farina, V. Tetrahedron 1993, 49, 2805-2828.
30. b) Johnson, R.A.; Nidy, E.G.; Dobrowolski, P.J.; Gebhard, L; Quails, S.J.; Wicnienski, N.A.; Kelly, R.C. Tetrahedron Lett. 1994, 35, 7893-7896.
31. c): Zheng, Q.Y.; Darbie, L.G.; Cheng, X.; Murray, C.K. Tetrahedron Lett. 1995, 36, 2001-2004.
32. Appendino, G.; Cravotto, G.; Enriù, R.; Gariboldi, P.; Barboni, L.; Torregiani, E.; Gabetta, B.; Zini, G.; Bombardelli, E. J. Nat. Prod. 1994, 57, 607-613.
33. Chattopadhyay, S.K.; Sharma, R.P. Phytochemistry 1995, 39, 935-936.
34. Ettouati, L.; Ahond, A.; Convert, O. Laurent, D.; Poupat, C.; Potier, P. Bull. Soc. Chim. Fr. 1988, 749-755.
35. See for instance: Datta, A.; Jayasinghe, L.R.; Georg, G.I. J. Org. Chem. 1994, 59, 4689-4690.
36. 22
37. Only the less hindered 7-TES group could be selectively removed with 1 mol. equiv. TBAF.
38. For a review on the synthesis of the side chain of antitumour taxoids, see: Kant, J. In The Chemistry and Pharmacology of Taxol® and Related Compounds; Farina, V., Ed.; Eisevier, 1995, pp.255-300.
39. Discrepancies of this type were first reported for a 11(15→1)abeo analogue of paclitaxel (Samaranayake, G.; Magri, N.F.; Jitrangsri, C.; Kingston, D.G.I. J. Org. Chem. 1991, 56, 5114-5119). Synthetic paclitaxelanalogues which improved tubulin affinity but a remarkably reduced cytotoxicity have been recently reported (Kalr, U.; Graf, H.; Schenk., O.; Röhr, B.; Schulz, H. Bioorg. Med. Chem. Lett. 1998, 8, 1397-1402).
40. Discrepancies of this type were first reported for a 11(15→1)abeo analogue of paclitaxel (Samaranayake,G.; Magri, N.F.; Jitrangsri, C.; Kingston, D.G.I. J. Org. Chem. 1991, 56, 5114-5119). Synthetic paclitaxel analogues which improved tubulin affinity but a remarkably reduced cytotoxicity have been recently reported (Kalr, U.; Graf, H.; Schenk., O.; Röhr, B.; Schulz, H. Bioorg. Med. Chem. Lett. 1998, 8, 1397-1402).
41. These assays were carried out according to: All, S.M.; Hoemann, M.Z.; Aubé, J.; Mitscher, L.A.; Georg, G.I.; McCall, R.; Jayasinghe, L.R. J. Med. Chem. 1995, 38, 2821-2828.